Recent Updates
Recently added Catalysts
LAB Positive Sentiment Score: 70/100

Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Key Takeaway: Standard BioTools Inc. has announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, scheduled for March 21, 2023. CEO Michael Egholm will engage in a fireside chat during this event. The presentation will be webcast live and accessible via the company's Investor Relations webpage. Standard BioTools, formerly known as Fluidigm Corporation, focuses on developing next-generation technologies for biomedical research.

Market Sentiment Analysis

POSITIVE FACTORS

  • Standard BioTools is actively promoting its innovations in human health.
  • Participation in a renowned investor forum may attract potential investors.
  • The company demonstrates leadership in advancing biomedical research technologies.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 3:00 p.m. ET.
The presentation will be webcast live and available on the Investor Relations page of the company’s website at Events & Presentations. A recording of the webcast will be archived and available on the Standard BioTools™ Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn®, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, and “Unleashing tools to accelerate breakthroughs in human health” are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Scott R. Greenstone, CFA

Frequently Asked Questions

What is Standard BioTools Inc.'s main mission?

Their mission is to unleash tools that accelerate breakthroughs in human health.

Who is participating in the KeyBanc Investor Forum?

Michael Egholm, PhD, President and CEO, will participate in the forum.

When will the KeyBanc fireside chat take place?

It will occur on March 21, 2023, at 3:00 p.m. ET.

Where can I watch the webcast of the presentation?

The webcast will be available on the Investor Relations page of their website.

What technologies does Standard BioTools specialize in?

They specialize in mass cytometry and microfluidics technologies.

Last updated: Mar 14, 2023